12:00 AM
Mar 12, 2012
 |  BC Week In Review  |  Company News  |  Deals

Gilead, Idenix deal

The U.S. Patent and Trademark Office declared a patent interference between a patent application from Idenix and U.S. Patent No. 7,429,572 owned by Gilead. Both patents cover the use of nucleoside compounds to treat HCV infection. The PTO is seeking to determine which company is entitled to patent...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >